Regeneron Pharmaceuticals, Inc. (REGN) EPS Estimated At $5.13

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Logo
Investors sentiment decreased to 0.94 in 2019 Q2. Its down 1.02, from 1.96 in 2019Q1. It turned negative, as 69 investors sold Regeneron Pharmaceuticals, Inc. shares while 179 reduced holdings. 60 funds opened positions while 174 raised stakes. 71.24 million shares or 0.02% less from 71.25 million shares in 2019Q1 were reported.
High Pointe Capital Mngmt Limited Com has invested 1.89% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Retirement Of Alabama accumulated 36,674 shares. Mackenzie Financial invested in 961 shares. 106,279 were accumulated by State Board Of Administration Of Florida Retirement System. Ls Advsrs Limited Liability Corp has invested 0.05% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). 149,382 are owned by Apg Asset Management Nv. 1,657 are owned by Blair William And Il. Renaissance Techs Lc holds 337,962 shares. Kentucky Retirement Ins Fund reported 1,640 shares or 0.1% of all its holdings. Hilton Cap Mngmt Ltd Limited Liability Company invested 0% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Alps Advsr reported 0% stake. 10 are held by San Francisco Sentry (Ca). Qs Invsts Ltd Co owns 15,045 shares. Dekabank Deutsche Girozentrale holds 0.09% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) or 59,672 shares. 2,499 are owned by Putnam Investments Ltd Limited Liability Company.

Since September 10, 2019, it had 0 insider buys, and 1 sale for $48.61 million activity.

Analysts expect Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to report $5.13 EPS on November, 5.They anticipate $0.03 EPS change or 0.59 % from last quarter’s $5.1 EPS. REGN’s profit would be $550.21M giving it 13.79 P/E if the $5.13 EPS is correct. After having $5.29 EPS previously, Regeneron Pharmaceuticals, Inc.’s analysts see -3.02 % EPS growth. The stock increased 0.79% or $2.21 during the last trading session, reaching $282.93. About 451,301 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 17.97% since October 7, 2018 and is downtrending. It has underperformed by 17.97% the S&P500.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, makes, and commercializes medicines for the treatment of serious medical conditions worldwide. The company has market cap of $30.35 billion. The Company’s products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes. It has a 15.71 P/E ratio. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer.

More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: which released: “3 Cancer-Fighting Drug Stocks to Buy Right Now –” on October 03, 2019, also with their article: “Regeneron’s evinacumab successful in late-stage study in inherited type of high cholesterol – Seeking Alpha” published on August 14, 2019, published: “Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Insiders Have Been Selling – Yahoo Finance” on June 12, 2019. More interesting news about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: and their article: “Regeneron Pharmaceuticals, Inc. Common Stock (REGN) Press Releases – Nasdaq” published on September 19, 2019 as well as‘s news article titled: “Here’s the Bad News That Derailed Regeneron’s Stock – Motley Fool” with publication date: May 08, 2019.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.